Multicenter Prospective Study Protocol for Validating Surgical Quality Standards in D3 Lymphadenectomy for Oncological Right Hemicolectomy

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundació d'investigació Sanitària de les Illes Balears

About this trial

Introduction: D3 lymphadenectomy (D3L) for right hemicolectomy, proposed by Eastern guidelines, aims to improve oncological outcomes by extending resection to include lymphatic drainage zones beyond those addressed by complete mesocolic excision (CME). However, the absence of standardized anatomopathological quality parameters limits its validation. This multicenter study seeks to validate this criteria, including the "right mesocolic sail," to classify D3L specimens and evaluate its clinical and oncological implications.

Materials and Methods: This prospective, multicenter study involves 11 hospitals in Spain. Surgical specimens from right hemicolectomy with D3L will be analyzed for the presence of the "right mesocolic sail" and classified as complete or incomplete D3L. Standard CME criteria will also be applied. Patient data, surgical details, and oncological outcomes at 3 and 5 years will be collected. Statistical analysis will compare lymph node retrieval, recurrence rates, survival outcomes, and perioperative complications between groups.

Results: The study will validate the right mesocolic sail as a quality parameter for D3L. Preliminary data from prior phases confirm increased lymph node retrieval and the presence of positive nodes in D3L specimens. Additional analyses will determine the impact of D3L on recurrence rates, survival, and perioperative risks.

Discussion: This study aims to provide standardized anatomopathological criteria to evaluate D3L, facilitating comparative studies and addressing its controversial oncological benefits. If validated, the criteria could enhance surgical quality assessment and inform future guidelines.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The study includes consecuent patients undergoing either elective or emergency surgery with a diagnosis of adenocarcinoma or adenoma with dysplasia located in the cecum, ascending colon, or hepatic flexure of the colon.

Disqualifiers

Patients under 18 years of age or lack of informed consent for inclusion in the study.

Trial population

Patients diagnosed of right colon neoplams undergoing elective or emergency surgery.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Right Colectomy & D3 Lymphadenectomy

    Procedure/Surgery

    Patients enrolled would receive a right colectomy with dissection of the Lymphoadipose tissue over the superior mesenteric vein, including all the tissue from the ileocolic vessels to the superior right colic vein.

Treatment groups

120 Participants
are divided into 1 treatment group
Group A: Patients with right colon neoplasm1 intervention

Trial outcomes

Primary outcomes

1

Complete or Incomplete D3L

Validation of Anatomopathological Criteria for Quality Assessment: to validate, through a multicenter study, the effectiveness of new anatomopathological criteria for right hemicolectomy with D3 lymphadenectomy (D3L) in accurately classifying surgical specimens as complete or incomplete D3L.

Time frame
From enrollment to the end of treatment at 8 weeks

Secondary outcomes

1

Total Number of Lymph Nodes Retrieved

To evaluate the total number of lymph nodes retrieved following D3 lymphadenectomy Unit of Measure: Number of lymph nodes

Time frame
From enrollment to the end of treatment at 8 weeks"
2

Positive Lymph Nodes Retrieved from the D3 Lymphadenectomy Area

To determine the presence and number of positive lymph nodes within the D3 lymphadenectomy area. Unit of Measure: Number of positive lymph nodes

Time frame
From enrollment to the end of treatment at 8 weeks
3

Perioperative Complications

To assess the incidence and severity of perioperative complications following right hemicolectomy with D3 lymphadenectomy, according to the Clavien-Dindo classification.

Time frame
From enrollment to the end of treatment at 30 days.
4

Local Recurrence

To assess the rate of local recurrence following right hemicolectomy with D3 lymphadenectomy.

Time frame
From enrollment to the end of treatment at 5 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fundació d'investigació Sanitària de les Illes Balears

Lead sponsor

Hospital Universitari de Bellvitge

Collaborator

Hospital Universitario La Fe

Collaborator

Hospital Universitario Marqués de Valdecilla

Collaborator

Hospital Universitari Vall d'Hebron Research Institute

Collaborator

Hospital General Universitario Gregorio Marañon

Collaborator

Hospital Universitario Ramon y Cajal

Collaborator

University Hospital of Girona Dr. Josep Trueta

Collaborator

Hospital General Universitario Reina Sofía de Murcia

Collaborator

Hospital del Mar

Collaborator

Hospital Son Espases

Collaborator

Hospital Álvaro Cunqueiro

Collaborator

This trial is not recruiting at the moment. You can still explore other options: